UBS Raises Illumina Target Price to $133, Maintains 'Neutral' Rating
Aug 08, 2024 17:43
CST Updated
17:43
Illumina
Diagnostic Product Developer
Gelonghui August 8 | UBS: Raised Illumina's target price from $131 to $133, maintaining a "neutral" rating.